BEDMINSTER, N.J., Feb. 29 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., executive vicepresident, chief operating officer, and chief executive officer-elect isscheduled to present at the Lehman Brothers Eleventh Annual Global HealthcareConference in Miami on Wednesday, March 19, 2008 at 3:15 p.m. ET. Thepresentation will be available as a live webcast with a replay availableapproximately 24 hours after the presentation has concluded. Interestedparties may access the webcast from the NPS website, http://www.npsp.com.
About NPS Pharmaceuticals
NPS Pharmaceuticals is developing high value specialty therapeutics forgastrointestinal and endocrine disorders. The company is currently advancingtwo late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinicaldevelopment for intestinal failure associated with short bowel syndrome andparathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinicaldevelopment as a hormone therapy for hypoparathyroidism. NPS has alsocompleted a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84[rDNA origin] injection). NPS complements its internal programs withstrategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, andNycomed. Additional information is available at http://www.npsp.com.
SOURCE NPS Pharmaceuticals, Inc.